Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
about
The role of preoperative systemic treatment in patients with breast cancerTRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKKβ/AMPKα/mTOR pathwayPrognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients.Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy.Dual roles for immune metagenes in breast cancer prognosis and therapy prediction.Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.Measuring proliferation in breast cancer: practicalities and applications.Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewKi-67 biomarker in breast cancer of Indian womenPredictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer.Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy.Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancerExpression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response.Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes.Molecular basis for therapy resistance.Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.Histopathologic changes following neoadjuvant chemotherapy in various malignancies.Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.Abnormal expression of the Notch and Wnt/β-catenin signaling pathways in stem-like ALDH(hi)CD44(+) cells correlates highly with Ki-67 expression in breast cancerMolecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.Predicting adverse drug reaction profiles by integrating protein interaction networks with drug structures.Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy.
P2860
Q26746034-D137B473-CF96-4AB2-B84D-6822D9A93598Q33784625-B36A2412-3AAC-4D55-8D7D-69EF2766874BQ34029132-5C5B3378-A422-4EB4-A783-417042C4B67DQ34265841-20F4AB7C-BB79-472C-85F3-E06672875E0DQ34558758-C1D2EB3F-FA3F-409C-9294-4C3C14837EA2Q34703634-8436240D-2E46-4509-BD27-2E26F3DFC7CBQ35012858-8409B432-99DE-4A29-811A-B571DB77869DQ35051660-2DE92946-425D-4058-9FED-0BAAA466056FQ35145309-16830CD7-182D-4573-82EC-E5FDC4B50FB9Q35558914-3E1D75E4-BF7D-4CAE-AEBF-E73E0C9E982DQ35633693-013C164F-3E74-4CF8-A284-DCC89C754980Q35832458-6E269BD9-CF87-45E5-B9B5-8D9C799D0DF2Q35854369-DE7F559F-B9F4-4DC3-B0AC-FB77001F50F1Q35904441-F5B7EDBC-3BD5-4411-BC2D-E6D4AFD39FB8Q35913434-0D2404E4-EFAA-4207-9F88-070D4CE0DAFEQ36225020-A847B715-7AB8-4E86-A7A2-D3F8EA09C848Q36615222-A9F9A9B5-1853-4605-B52F-59F4A6A8A5CEQ36797262-2E9B2D4A-2DF1-483E-931C-8D0652B2B5F3Q36977587-BB882D2D-8E6E-4EB8-B232-44C40344A29BQ37176101-F6F0E394-45EF-4F67-9735-29FBBE1EF760Q37424040-EF4BC23D-35D8-48EF-8217-F34E271AF858Q37484652-75F76B48-AEDC-4276-A176-DBAC7FED22D1Q37688879-304FC067-C87C-4F89-979C-09052DF3D80FQ37751530-D93B3359-0CF8-45F8-8138-AB5782ECFDBAQ37835106-BF8BC488-FEFE-49A8-A401-67EFB115D3B7Q38115304-D8D43629-793C-4B9D-B825-7EFC4E12C862Q38397572-F995D3C6-9AAA-4EE9-8E6D-18EF526168BAQ41194558-89745802-CEBD-43D9-8C30-C84023C14677Q42745161-44444C0F-070B-46E3-A923-25A95335BFA0Q46614726-AD45AE4B-3172-4416-853C-74640C956A3BQ50734440-701F4A87-D6DD-45FA-831C-F01FF3AEC345Q53150503-3CC7DA4D-46D2-463A-A3BA-B6ABDC4E3693Q54649694-A1DD3E6D-ACB1-4890-BD23-E144DC5AC7E2Q55273676-974DAFA9-57CE-4F4D-B983-C243C4EBF540
P2860
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Evaluation of ER, PgR, HER-2 a ...... apy for operable breast cancer
@ast
Evaluation of ER, PgR, HER-2 a ...... apy for operable breast cancer
@en
type
label
Evaluation of ER, PgR, HER-2 a ...... apy for operable breast cancer
@ast
Evaluation of ER, PgR, HER-2 a ...... apy for operable breast cancer
@en
prefLabel
Evaluation of ER, PgR, HER-2 a ...... apy for operable breast cancer
@ast
Evaluation of ER, PgR, HER-2 a ...... apy for operable breast cancer
@en
P2093
P2860
P356
P1476
Evaluation of ER, PgR, HER-2 a ...... apy for operable breast cancer
@en
P2093
Burcombe RJ
Richman PI
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602256
P407
P577
2005-01-01T00:00:00Z